Safety and efficacy of neoadjuvant chemotherapy with paclitaxel, carboplatin, and cetuximab for locally advanced head and neck squamous cell carcinoma

• DOI: 10.1007/s10147-024-02545-9
• Publication Date: 2024-05-10T14:01:57Z
• Authors: Ryoko Tanaka; Yushi Ueki; Shusuke Ohshima; Jo Omata; Yusuke Yokoyama; Takeshi Takahashi; Ryusuke Shodo; Keisuke Yamazaki; Kohei Ohtaki; Takafumi Togashi; Arata Horii
• Keywords: Male; Aged, 80 and over; Adult; Paclitaxel; Squamous Cell Carcinoma of Head and Neck; Cetuximab; Middle Aged; Neoadjuvant Therapy; Carboplatin; Head and Neck Neoplasms; Antineoplastic Combined Chemotherapy Protocols; Humans; Female; Aged; Retrospective Studies

As a substantial waiting time is usually required for radical surgery, safe and effective preoperative neoadjuvant chemotherapy (NAC) is desired for the treatment of locally advanced head and neck squamous cell carcinoma (HNSCC). However, the significance of NAC in advanced HNSCC is still unclear. This study aimed to assess the safety and efficacy of NAC using the paclitaxel, carboplatin, and cetuximab (PCE) regimen.We retrospectively evaluated the background characteristics, incidence of adverse events, overall response rate (ORR), pathological response, recurrence-free survival (RFS), and overall survival (OS) in 26 patients. Patients receiving the PCE regimen were further divided into two groups based on the number of chemotherapy cycles (one cycle or more) and eligibility for cisplatin. Patients aged ≥ 75 years and those with an estimated glomerular filtration rate (eGFR) < 60 mL/min were classified as ineligible for cisplatin.The median age was 70 (27-81) years. The median eGFR at treatment initiation was 63.2 (41.1-89.7) mL/min. Fourteen (53.8%) patients were ineligible for cisplatin. Grade 3 or higher neutropenia was observed in 11 of 25 (42.3%) patients. No delay in or withdrawal from surgery was observed. The ORR was 65.4%. The 2-year RFS and OS were 61.5% and 76.7%, respectively. No significant differences in safety and efficacy between the number of chemotherapy cycles and cisplatin eligibility were observed.NAC using the PCE regimen for patients with locally advanced HNSCC, including cisplatin-ineligible patients, has acceptable toxicity and favorable efficacy.